These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24145547)

  • 21. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
    Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.
    Lim S; Bast D; McGeer A; de Azavedo J; Low DE
    Emerg Infect Dis; 2003 Jul; 9(7):833-7. PubMed ID: 12890324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
    Jorgensen JH; Weigel LM; Swenson JM; Whitney CG; Ferraro MJ; Tenover FC
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2962-8. PubMed ID: 11036007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae.
    Madaras-Kelly KJ; Daniels C; Hegbloom M; Thompson M
    J Antimicrob Chemother; 2002 Aug; 50(2):211-8. PubMed ID: 12161401
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Murata M; Kosai K; Yamauchi S; Sasaki D; Kaku N; Uno N; Morinaga Y; Hasegawa H; Miyazaki T; Izumikawa K; Mukae H; Yanagihara K
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29439959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Global Regulatory Cyclic AMP Receptor Protein (CRP) Controls Multifactorial Fluoroquinolone Susceptibility in Salmonella enterica Serovar Typhimurium.
    Kary SC; Yoneda JRK; Olshefsky SC; Stewart LA; West SB; Cameron ADS
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights into the evolutionary trajectories of fluoroquinolone resistance in Streptococcus pneumoniae.
    Zhang G; Wang C; Sui Z; Feng J
    J Antimicrob Chemother; 2015 Sep; 70(9):2499-506. PubMed ID: 26031465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
    Garrison MW; Schimmels JA; Madaras-Kelly KJ
    Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae.
    El Garch F; Lismond A; Piddock LJ; Courvalin P; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2010 Oct; 65(10):2076-82. PubMed ID: 20709735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular determinants of the bacterial resistance to fluoroquinolones: a computational study.
    Lupala CS; Gomez-Gutierrez P; Perez JJ
    Curr Comput Aided Drug Des; 2013 Jun; 9(2):281-8. PubMed ID: 23106777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoroquinolone-nonsusceptible Streptococcus pneumoniae isolates from a medical center in the pneumococcal conjugate vaccine era.
    Chen HH; Li HC; Su LH; Chiu CH
    J Microbiol Immunol Infect; 2017 Dec; 50(6):839-845. PubMed ID: 27342636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
    Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
    Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Garvey MI; Baylay AJ; Wong RL; Piddock LJ
    Antimicrob Agents Chemother; 2011 Jan; 55(1):190-6. PubMed ID: 20937787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.